Evidence map›Paper›PMID 42638435›Full record

ArticleJournal of applied clinical medical physics2026

Dynamic modulated arc therapy (DMAT): A time-aware, modulation-steered optimization framework for next-generation radiotherapy delivery.

Taoran Li, Esa Kuusela, Emmi Ruokokoski, Heini Hyvönen, Jerry Jaboin, Mirko Myllykoski, Jussi Nurminen, Riku Paananen, Jarkko Peltola, Marko Rusanen and 3 more

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Taoran LiVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Esa KuuselaVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Emmi RuokokoskiVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Heini HyvönenVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Jerry JaboinVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Mirko MyllykoskiVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Jussi NurminenVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Riku PaananenVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Jarkko PeltolaVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Marko RusanenVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Martin SabelVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Kevin MooreVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.
Christopher BoylanVarian Medical Systems Inc., a Siemens Healthineers company, Palo Alto, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConventional VMAT optimization largely treats delivery time and deliverability as emergent properties of simplified, control-point-centric models that often ignore finite acceleration and other dynamic limits. As modern linacs continue to increase maximum axis speeds and dose rates, there is a growing need for a planning paradigm that makes the plan quality-time trade-off explicit and steerable, especially when shorter treatments can provide clinical benefits beyond throughput. PURPOSE: This work introduces Dynamic Modulated Arc Therapy (DMAT), a time-aware, modulation-steered framework that jointly optimizes dosimetric quality, delivery time, and modulation complexity. Here, time-aware denotes that delivery time is computed within the optimizer from an explicit model of machine dynamics, including finite acceleration and axis synchronization, rather than inferred after optimization; modulation-steered denotes that leaf-travel allowance, control-point density, total monitor units (MUs), and aperture complexity are governed together by a single user-selected modulation level, making the amount and distribution of modulation an explicit input to the optimizer. Clinical goals enter the optimizer as metric-based cost functions defined by each criterion's metric, goal value, acceptable variation, and priority, with supporting objectives generated automatically.

methodsDMAT couples (1) direct machine emulation that accounts for axis synchronization and dynamic limits, (2) dynamic modulation control, and (3) clinical metrics as optimization cost functions. A user-selected modulation level (-3 to +3) governs leaf-travel allowance, total MU behavior, aperture-complexity penalties, and control-point (CP) density. Plans are created by defining a treatment trajectory, initializing CP geometry, leaf positions, and MU, then iteratively improving the solution with a progressive-resolution loop alternating dosimetric updates with sequencing/deliverability updates, followed by post-processing to reduce complexity with minimal dose change. CP density is adapted nonuniformly: a preliminary uniform-CP optimization is followed by redistribution according to combined delivery-complexity and geometric information. DMAT was evaluated using a hypothetical accelerated C-arm delivery system (max gantry speed 2.5 RPM, max MLC speed 6.25 cm/s, max dose rate 3000 MU/min) on representative head-and-neck, lung SBRT, and prostate SBRT cases.

resultsAcross all cases, increasing modulation level produced plans with increased modulation surrogates (e.g., MU/Gy and aperture complexity) and progressively longer delivery time, while adaptive non-uniform CP allocation concentrated additional CPs in arc sectors where higher angular resolution was most beneficial. The resulting quality-time trade-off space was disease site dependent: the head-and-neck case showed substantial plan-quality gains with increased modulation and CP density, whereas prostate SBRT and lung SBRT exhibited smaller incremental quality improvements beyond baseline despite longer delivery times. When efficiency was prioritized (negative modulation levels), DMAT predictably reduced modulation and maintained a constant CP budget while shortening delivery time, producing corresponding and quantifiable reductions in plan quality.

conclusionsDMAT establishes a time-aware, modulation-steered planning and delivery methodology in which plan quality and modulation complexity are co-optimized under explicit clinical and user control using machine-aware timing. Accurate delivery time is exposed to users during planning through advanced machine emulation. By doing so, DMAT makes quality-time trade-offs transparent, predictable, and navigable, providing a practical foundation for leveraging next-generation delivery systems' capabilities and supporting time-constrained workflows such as motion-sensitive treatments and adaptive radiotherapy.

Indexed as

AlgorithmsHead and Neck NeoplasmsNeoplasmsParticle AcceleratorsPhantoms, ImagingRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedHumansOrgans at RiskRadiotherapy Dosageadaptive radiotherapydelivery timedynamic modulated arc therapymachine emulationmodulation complexitytreatment planningVMAT

Identifiers

PMID42638435
PMCPMC13504227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.